Role of cardiac resynchronization therapy in the development of new-onset atrial fibrillation:  A single-center prospective study. by Gaetano Santulli et al.
 1 
Role of cardiac resynchronization therapy in the development of new-onset atrial fibrillation: 
 A single-center prospective study. 
 
 
Gaetano Santulli, MDa,b,*, Massimo Chiariello, MDa,†, Cristofaro d’Ascia, MD and Salvatore Luca d’Ascia, MDa 
a:Division of Cardiology, Department of Clinical Medicine, Cardiovascular and Immunologic Sciences,  
“Federico II” University, Naples, Italy; 
b:Columbia University Medical Center, Manhattan, New York, NY - USA. 
 
 
†:Since this paper was submitted this author has died 
 
 
 
 
 
 
 
 
 
*Corresponding Author: Dr. Gaetano Santulli 
E-mail address: gaetano.santulli@unina.it 
 
 
Word Count: 2541  
 
Conflict of interest: none declared. 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.7
13
7.
1 
: P
os
te
d 
3 
Ap
r 2
01
2
 2 
Albeit several studies examined the association between cardiac resynchronization therapy (CRT) and atrial 
fibrillation (AF) in heart failure (HF), results are still unclear and quite conflicting. We thereby designed a 
single-center prospective study to determine whether CRT has a favorable effect on the incidence of new-onset 
AF in a homogeneous population of patients with non-ischemic idiopathic dilated cardiomyopathy and severe 
heart failure HF. We enrolled 58 patients, AF naïve when received CRT. After 1 year of follow-up our 
population was subdivided into responders (72.4%) and non (27.6%), so to compare the incidence of AF after 
1, 2 and 3 years of follow-up in these two groups. Already after 1 year, there is a significant (p<0.05) difference 
in new-onset AF in non-responder patients respect to responders (18.2% vs 3.3%). These data are confirmed at 
2 year (33.3% vs 12.2%) and 3 year (50.0% vs 15.0%) follow-up. In particular, at 3 year follow-up, non-
responders have an increased risk to develop new-onset AF (OR=5.67, 95% confidence interval = 1.36-23.59, 
p=0.019). The present work suggests a possible favorable role of this non-pharmacological therapy, on the 
prevention of AF. 
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Introduction 
Several studies have showed the hemodynamic and functional improvement obtained with cardiac 
resynchronization therapy (CRT) in patients with advanced heart failure (HF) and ventricular conduction 
delay.(Anand et al., 2009; Cleland et al., 2009; Mullens et al., 2009; Yancy et al., 2009) Nevertheless, despite 
the positive effects of CRT on hemodynamic, functional status, and mortality in HF, approximately 30% of 
patients do not respond to this therapy, emphasizing the need for better selection criteria.(Anand et al., 2009; 
Cleland et al., 2009)  
Furthermore, the primary cardiac cause of exacerbation of HF is atrial fibrillation (AF), that is also an 
independent risk factor for sudden death.(Capucci, 2009) HF and AF often coexist;(Adelstein et al., 2007) both 
are responsible for increased mortality, more frequent hospitalizations, reduced exercise capacity, and 
decreased quality-of-life (QoL). Besides, AF and HF are believed to directly predispose to each other.(Larned 
et al., 2009) In particular, in the setting of advanced HF, 30% to 40% of patients will develop AF during the 
course of the disease.(Stevenson et al., 1999) So, if CRT influences the occurrence of AF, this might influence 
patient selection and possibly programming of the device.(Hsia, 2006) 
The aims of the present study were: to identify pre-implantation characteristics that best can predict which 
patients will benefit the most from biventricular pacing, in order to make out suitable candidates for CRT;(Bax 
et al., 2009) to compare the incidence of new-onset AF(Adelstein et al., 2007) after 1, 2 and 3 years of follow-
up in responder and non-responder patients, so to assess a possible favorable role of CRT, through means of an 
atrial reverse remodeling, on the prevention of this arrhythmia. 
 
Methods 
All patients with non-ischemic idiopathic dilated cardiomyopathy had New York Heart Association 
(NYHA) functional class III or IV symptoms (D'Ascia et al., 2006; Vardas et al., 2007) for at least six months 
before enrollment, despite optimal pharmacological treatment (including β blockers, loop diuretics, 
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vasodilators, nitrate, digitalis, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and 
spironolactone when tolerated), left ventricular ejection fraction (LVEF) ≤ 35%, and QRS duration ≥ 150 ms 
measured on at least 3 leads on the surface ECG. Exclusion criteria were: recent (previous 3 months) acute 
coronary syndrome or planned coronary revascularization, previous pacemaker or implantable cardioverter 
defibrillator (ICD) implantation, requirement of continuous intravenous therapy, a life expectancy of <1 year 
due to non- cardiac diseases, pre-existent AF, patients whose major echocardiographic parameters could not be 
obtained cause of poor image quality, systolic blood pressure >170 or <80, heart rate >140, and kidney failure 
with serum creatinine levels >250 µmol/L.(Vardas et al., 2007) 
Detailed clinical and instrumental data (ECG, echocardiogram, QoL evaluation, 6-min walk test, 
cardiopulmonary exercise test) were collected, with scheduled visits, before implantation and at the 1-, 2- and 
3-year follow-up. The detection of AF relied on electrocardiography, 24h Holter examination and strips from 
continuous telemetric control of implanted devices.(D'Ascia et al., 2009) AF was defined as an episode, with or 
without symptoms, lasting at least 10 minutes,(Fung et al., 2005; Glotzer et al., 2003) similar to a large sub-
study of the CARE-HF trial reported by Hoppe et al.(Hoppe et al., 2006) Patients were also assessed for HF 
symptoms (NYHA functional class). QoL was evaluated by the Minnesota Living with HF questionnaire 
(scores range from 0 to 105, with higher scores reflecting a poorer QoL),(Rector et al., 1992) while the 6-min 
walk test was carried out according to Bittner’s recommendations.(Bittner, 1997) Study nurses who had no 
knowledge of the patients’ treatment administered the 6-min walk distance and QoL tests. Coronary 
angiography was performed prior to implantation in all patients, also to exclude causes of HF amenable to 
surgery or intervention. This study protocol was designed in compliance with the Helsinki declaration and 
approved by the local Ethics Committee. Written informed consent was obtained from each participant. 
Non-responders were defined after 12 months of follow-up as patients with at least one of the following 
characteristics: deteriorating function (HF-related death, need for heart transplantation), increase in LVEF ≤ 4 
absolute percentage points, worsening in peak oxygen consumption, in QoL score or in the distance walked in 6 
min, as previously described.(St John Sutton et al., 2003) 
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ICD implantation and optimization: Patients were implanted with a biventricular ICD (Contak 
Renewal 1 or 2, Guidant Inc.). All procedures were performed under local anesthesia. Three transvenous leads 
were inserted, through the left subclavian vein. The atrial lead was placed in the high right atrium; the right 
ventricular lead was positioned, in the apex or in the high interventricular septum, as far as possible from the 
LV lead; LV pacing was obtained after coronary sinus (CS) angiography, advancing a bipolar lead into the 
lateral or posterolateral cardiac vein. The final lead position was chosen on the basis of visual inspection, 
assessed by anteroposterior and lateral chest radiography.(D'Ascia et al., 2006; Leon et al., 2005) The 
atrioventricular interval (electrical delay between atrial and ventricular excitation) was optimized by Doppler 
echocardiography 1 day after implantation to reach maximal transmitral diastolic filling and maximal 
biventricular capture,(Jansen et al., 2007) and checked every year. Patients in which transvenous LV lead 
implantation was acutely unsuccessful (n=5), due to several causes [failure to cannulate the CS (n=2), high 
threshold to chronic pacing (n=1), CS dissection (n=1) and impossibility to obtain a stable lead 
placement(n=1)] were obviously excluded from the study. 
Echocardiographic evaluation: A trans-thoracic, two-dimensional echocardiogram was serially 
performed in all patients using a Sonos 5500 ultrasound system (Philips), equipped with a 2.5-MHz transducer. 
The examination included two-dimensional, M-mode and Doppler data. All recordings were made, as 
previously described, with the patient in the lateral recumbent position, according to the American Society of 
Echocardiography recommendations.(Bax et al., 2009) The following parameters were measured using the 
different axis: LV end-diastolic and end-systolic diameters, LVEF (biplane LV end-systolic and end-diastolic 
volumes were calculated from apical views according to the modified Simpson’s rule), LV end-systolic volume 
index, left atrial diastolic and systolic areas, amount of mitral regurgitation (calculated as the area of the color-
flow Doppler regurgitant jet divided by the area of the left atrium in systole, both in square centimeters). All 
echocardiographic studies were performed and analyzed by the same study-independent physicians, blinded to 
the study protocol and to the patients’ status. Echocardiographic measurements were systematically averaged in 
five consecutive samples. 
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Cardiopulmonary exercise test: Symptom-limited cardiopulmonary exercise testing (Treadmills 
‘Rammill Series’, Morgan Italia, Bologna, Italy) was performed, conducted on an upright bicycle ergometer 
with a 10-W/min step protocol, starting with 2 min of unloaded cycling. Measurements of oxygen consumption 
(VO2), were taken at rest and during exercise using a moving average of eight breaths. During each stage of 
exercise, data on heart rate and rhythm and BP were collected. All patients were encouraged to exercise until 
they felt unable to continue because of dyspnoea and/or fatigue. The ventilatory threshold was measured by the 
V-slope method.(Beaver et al., 1986) The maximum VO2 was defined as the highest VO2 value measured (peak 
VO2). 
Statistical analysis: Unless otherwise specified, data are presented as the mean value ± SD or absolute 
numbers with percentages for categorical variables, unless otherwise specified. Data normality was evaluated 
through the Kolmogorov-Smirnov test. Comparison of quantitative variables was performed using the Student’s 
t-test for paired and unpaired data when appropriate, with a Bonferroni correction when multiple comparisons 
were made. Dichotomous or categorical data were assessed with the χ2 test or Fisher’s exact test. The non-
normally distributed data within patient groups were compared using the nonparametric Wilcoxon test.(Santulli 
et al., 2009a; Santulli et al., 2012d) Odds ratios were given with the 95% confidence interval (CI). Differences 
in event rates (AF, death) over time were calculated according to the Kaplan-Meier method and analyzed with 
the use of Cox proportional hazard models. To identify predictors of lack of response to CRT, we performed a 
multivariable Cox regression, using a forward-step model, validated using an ‘n-1’ strategy. All tests that we 
performed were two-tailed and a p value <0.05 was considered statistically significant. All statistical tests were 
performed with the SPSS 16 statistical package (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.01 
(GraphPad software, San Diego, CA, USA). 
 
Results 
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Baseline characteristics of the patients are reported in Supplementary Table 1. The mean age was 62.5±11.1 
years; there was a male predominance (63.8%), with a mean LVEF of 27.57±5.6%. Drug therapy for HF did 
not change significantly over the follow-up period, and all patients had stable biventricular stimulation. 
After 1 year, 42 patients (72.4%) were considered responders to CRT according to the previously defined 
criteria. There were 16 non-responders (27.6%), with 4 HF-related hospitalizations. Two patients died before 
the 2-year follow-up visit (1 responder and 1 non); four patients died before the 3-year follow-up visit (1 
responder and 3 non). 
Our most interesting finding is that, already after 1 year, there is a significant difference in new-onset AF in 
non-responder patients (18.2%) vs responders (3.3%). These data are confirmed at 2 year (33.3% vs 12.2%) and 
3 year (50.0% vs 15.0) follow-up. In particular, at 3 year follow-up, non-responders have a markedly increased 
risk to develop new-onset AF (odds ratio = 5.67, 95% CI = 1.36-23.59, p=0.019). Thus, this disparity in risk 
persisted throughout the 3 year follow-up period. 
As regards the other purpose of our study, that is the identification of the pre-implantation parameters useful 
to select responder and non-responder patients, multivariate analysis identified independent predictive factors 
for non-responder patients. As already shown in previous studies,(Leclercq et al., 2008; Yu et al., 2005) neither 
age, electrical parameters, NYHA class, nor LVEF appear useful in predicting a response to pacing. 
Interestingly, we noticed the importance of LV end-diastolic diameter (73.2±9.1 mm in non-responder patients 
vs 68.1±7.1 mm in responders; p<0.05) and the degree of mitral regurgitation (0.28±0.02 in non-responders vs 
0.20±0.02 in responders; p<0.05). 
Moreover, as shown in Supplementary Table 2, there was a favorable improvement of clinical status in the 
group of CRT responders, evidenced already at 1 year follow-up, and corroborated after 2 and 3 years. 
Specifically, we evidenced the positive effects of CRT in NYHA functional class, LVEF, reduction of mitral 
regurgitation, 6-min walk test, Minnesota Living With HF QoL score, oxygen uptake at peak exercise and at 
anaerobic threshold.  
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Discussion  
The loss of coordination of ventricular contraction contributes to the pathophysiology of HF, reducing the 
already diminished contractile reserve of the heart.(Kass, 2008) Specifically, dyssynchronous contraction 
exacerbates inefficient use of energy by the heart (mechano-energetic uncoupling). Indeed, the left lateral wall 
is activated well after the septum contracts.(Sade et al., 2008) This leads to contraction of the lateral wall 
during relaxation of the septum resulting in marked mechanical dysfunction. The dyssynchronous failing heart 
exhibits also deep alterations in protein expression, (Santulli et al., 2011a; Santulli et al., 2009b; Vanderheyden 
et al., 2009) such as changes in local calcium handling, as exemplified by a strong decrease of phospholamban 
in the delayed activated myocardium.(Spragg et al., 2003) The purpose of CRT is to restore ventricular 
relaxation and contraction sequences by simultaneously pacing both ventricles. Numerous studies have reported 
positive long-term effects in terms of symptoms, exercise tolerance, QoL and HF prognosis after 
CRT,(Gasparini et al., 2008; Jansen et al., 2007; Leclercq et al., 2008) and our work confirms these findings. A 
prospective study examining the relation between CRT and AF using as control a HF population that doesn’t 
receive CRT would be neither ethical nor practical, given the proven efficacy of this therapy in treating HF. So, 
we decide to compare a homogeneous (Lanni et al., 2007; Santulli et al., 2011b) population of CRT recipients, 
then subdivided in responders and non. One of the most pressing unresolved questions, however, remained how 
to identify the patients that will not respond to CRT, and how to define response is really central to the entire 
question,(Bax et al., 2009; Yu et al., 2005) since there is relatively poor correlation between the various 
measures of CRT response. Thus, as mentioned in methods, we used clear and reproducible criteria for the 
definition of non-responder patients, also to avoid any case of misinterpretation. 
We recruited only patients with non-ischemic dilated cardiomyopathy. In fact, albeit CRT is an effective 
alternative therapy in patients with dilated heart disease whether of ischemic or non-ischemic origin, the 
response tends to be slightly lower when the heart disease is ischemic, maybe due to the presence of necrotic 
tissue. This is the first study that focalizes on this topic, assuring a homogeneous study population. Indeed, 
heterogeneity may explain controversial results concerning this issue emerged in literature. 
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Another chief issue to discuss in analyzing the occurrence of AF is how the same AF is detected. We 
defined AF as an episode, with or without symptoms, lasting 10 minutes or more, identified by 
electrocardiography, Holter examination and using the continuous monitoring capability offered by implanted 
devices, that were programmed uniformly to capture AF episodes.(Bottoni et al., 2004; Fuster et al., 2001; Toff 
et al., 2005) Other studies have used a variety of different definitions for AF, also relied on symptoms, which 
appear clearly inadequate in assessing overall AF burden. 
Despite the extensive evidence of the benefits of CRT on ventricular function, the data about the effects of 
CRT on atrial function and on the incidence of new-onset AF are conflicting.(Cleland et al., 2009; Fung et al., 
2005; Hoppe et al., 2006; Santulli et al., 2012a; Santulli et al., 2012b; Santulli et al., 2012c) The potential 
mechanisms to take into account for the effect attributed to CRT in the prevention of AF could be related to an 
improvement in left ventricular systolic function and a decrease of the degree of mitral regurgitation, with a 
reduction of structural atrial remodeling of the electrophysiological substrate responsible for the 
initiation/triggers of atrial arrhythmias.(Wijffels et al., 1997) Indeed, the fact that after 3 year follow-up non-
responder patients show an increased left atrial diastolic area than responders is a strong evidence for 
supporting the hypothesis that CRT may prevent AF through atrial reverse remodeling,(Wijffels et al., 1997) 
probably due to a reduction of the overload in the atria.(Sade et al., 2008) Anyway, atrial function is relatively 
complex, and more quantitative methods are needed to better explore atrial functional improvement. Moreover, 
because patients with HF who develop AF have a worse outcome,(Adelstein et al., 2007; Capucci, 2009; 
Larned et al., 2009; Santulli, 2012a; Santulli, 2012b) it could be interesting to know whether CRT might 
improve outcome. However, this is only a pilot study, with a small number of subjects, albeit they constitute a 
remarkable patient population, because of selective inclusion and exclusion criteria. So, the results must be 
interpreted cautiously, and further studies, pooling data from multiple centers, are needed to confirm our 
findings and to assess their real clinical impact. 
 
Conclusions 
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Our study shows that, after a follow-up of 3 years, in CRT non-responder patients there is a significant 
increased risk to develop new-onset AF. Moreover, we identified two echocardiographic parameters as 
predictors of lack of response to CRT: the LV end-diastolic diameter and the degree of mitral regurgitation. All 
these data can be useful in the selection and management of patients with HF. 
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